Key result
Hetastarch 670/0.75 continuous infusion prolongs platelet closure time in healthy dogs up to 24 hours.
Why the study?
Does hetastarch 670/0.75 administered as a constant rate infusion prolong platelet closure time in healthy dogs?
Does hetastarch 670/0.75 administered as a constant rate infusion prolong platelet closure time in healthy dogs?
Hetastarch 670/0.75 infusion prolongs platelet closure time in healthy dogs, particularly at higher doses and longer durations, without causing spontaneous bleeding.
Answers are grounded in this paper and cite their sources.
Hetastarch CRI effects on platelets in healthy dogs leave open bleeding risk in clinical veterinary patients; prospective trials needed.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Helmbold et al. (2014) studied Healthy (n=8). Hetastarch 670/0.75 vs. Baseline was evaluated on Platelet closure time (CT). Hetastarch 670/0.75 administered as a 24-hour constant rate infusion at 1 and 2 mL/kg/h significantly prolonged platelet closure time in healthy dogs at 6, 12, and 24 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: